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Abstract
Introduction In severely neutropenic septic acute respiratory
distress syndrome (ARDS) patients, macrophages and
monocytes are the last potentially remaining innate immune
cells. We have previously shown, however, a deactivation of the
alveolar macrophage in neutropenic septic ARDS patients. In
the present study, we tried to characterize in vitro monocyte
baseline cytokine production and responsiveness to
lipopolysaccharide exposure.
Methods Twenty-two consecutive patients with cancer were
prospectively enrolled into a prospective observational study in
an intensive care unit. All patients developed septic ARDS and
were divided into two groups: neutropenic patients (n = 12) and
non-neutropenic patients (n  = 10). All of the neutropenic
patients received granulocyte colony-stimulating factor whereas
no patient in the non-neutropenic group received granulocyte
colony-stimulating factor. We compared monocytes from
neutropenic patients with septic ARDS with monocytes from
non-neutropenic patients and healthy control individuals (n =
10). Peripheral blood monocytes were cultured, and cytokine
levels (TNFα, IL-1β, IL-6, IL-10, and IL-1 receptor antagonist)
were assayed with and without lipopolysaccharide stimulation.
Results TNFα, IL-6, IL-10 and IL-1 receptor antagonist levels in
unstimulated monocytes were lower in neutropenic patients
compared with non-neutropenic patients. Values obtained in the
healthy individuals were low as expected, comparable with
neutropenic patients. In lipopolysaccharide-stimulated
monocytes, both inflammatory and anti-inflammatory cytokine
production were significantly lower in neutropenic patients
compared with non-neutropenic patients and control individuals.
Conclusion Consistent with previous results concerning
alveolar macrophage deactivation, we observed a systemic
deactivation of monocytes in septic neutropenic ARDS. This
deactivation participates in the overall immunodeficiency and
could be linked to sepsis, chemotherapy and/or the use of
granulocyte colony-stimulating factor.
Introduction
The role of the host immune response in the pathogenesis of
septic acute respiratory distress syndrome (ARDS) remains
unclear. Indeed, cytokine-producing activated inflammatory
cells recruited to the lung are the major determinant of the
innate immune defense to respiratory pathogens [1]. The
impairment of the response facilitates infection and therefore
pathogen-mediated injury [1].
In patients severely neutropenic from exposure to radiation or
cytotoxic drugs, the recruitment of neutrophils into the lung is
an evidently impaired defense mechanism. In these patients,
ARDS = acute respiratory distress syndrome; G-CSF = granulocyte colony-stimulating factor; HLA-DR = class II major histocompatibility complex; 
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several other cellular populations taking part in the innate
immune response may remain available.
One alternative population may be activated alveolar macro-
phages, which can release a wide variety of mediators [2-5].
We recently demonstrated, however, a deactivation of alveolar
macrophages in neutropenic patients with ARDS [6]. Another
alternative population could be monocytes, whose role and
state of activation remains unclear in septic ARDS – although
several studies have found evidence of monocyte deactivation
in human sepsis [7,8].
Our hypothesis, therefore, was that monocytes could play a
major role, in addition to neutropenia, in the immunosuppres-
sion of neutropenic patients treated with granulocyte colony-
stimulating factor (G-CSF) and presenting septic ARDS. The
objective of our study was to find evidence of monocyte hypo-
reactivity in these patients.
To characterize monocyte hyporeactivity, we evaluated mono-
cyte cytokine production in vitro under basal conditions and
after lipopolysaccharide (LPS) exposure, using cultured mono-
cytes isolated from the blood of neutropenic patients treated
with G-CSF or non-neutropenic patients, both presenting sep-
tic ARDS. We also used healthy individuals' monocytes as a
control population.
Patients and methods
Patients
Twenty-two consecutive patients with cancer were prospec-
tively enrolled in the study. All patients had developed docu-
mented septic ARDS and were divided into two groups:
neutropenic patients (absolute neutrophil count <1,000/mm3)
treated with G-CSF, and non-neutropenic patients (absolute
neutrophil count >1,000/mm3).
We used the definition of ARDS recommended by the Ameri-
can–European Consensus Conference [9]. Sepsis was
defined according to the criteria of the American College of
Chest Physicians/Society of Critical Care Medicine Consen-
sus Conference [10]. The study was conducted after obtain-
ing approval from our institutional Ethics Committee; informed
consent was obtained from each patient's next of kin or
directly from the healthy volunteers.
Standard supportive cares as well as broad-spectrum antibiot-
ics were provided for each patient. All neutropenic patients
were treated with G-CSF prior to intensive care unit admis-
sion, whereas no patient received G-CSF in the non-neutro-
penic patient group. All patients underwent blood sampling
during the first 3 days after the onset of ARDS. The duration
of ARDS prior to monocyte harvesting was similar in neutro-
penic patients and non-neutropenic patients.
Isolation and culture of monocytes
Ten milliliters of blood were sampled, diluted in isotonic saline
and were centrifuged. The cellular pellet containing mononu-
clear cells was recovered, and monocytes were isolated by
plastic adherence and incubated with supplemented RPMI
1640 (10% fetal calf serum, 2 mM L-glutamate, 100 U/ml pen-
icillin, 100 mg/ml streptomycin) for 24 hours at 37°C. Endo-
toxin contamination was excluded by testing reagents with the
Limulus amebocyte lysate assay (Whittaker Bioproducts, Fon-
tenay-sous-Bois, France).
Monocyte activation and immunoassays for cytokine 
determination
Monocytes were cultured (5 × 105 cells/assay) in RPMI 1640
containing 10% fetal bovine serum and antibiotics in the pres-
ence or the absence of LPS (Escherichia coli extract, 055:B5;
Sigma, St Louis, MO, USA) for 16 hours at 37°C. Cell super-
natants were collected and stored at -70°C before assays.
Cytokine measurements were performed with a quantitative
sandwich enzyme immunoassay (R&D Systems, British Bio-
technology, Abingdon, UK). Supernatants were assayed for
TNFα, IL-1β, IL-6 and IL-10 with enzyme immunoassays pro-
vided by Immunotech (Marseille, France). IL-1 receptor antag-
onist was assayed using a kit provided by R&D Systems. The
intra-assay and inter-assay coefficients of variation of the
immunoassay kits ranged between 5% and 10%.
Statistical analysis
Comparisons between two independent groups were ana-
lyzed by the Mann–Whitney U test. For dichotomous data, per-
centages were calculated and were compared using Fisher's
exact test. To assess whether cytokine production was modi-
fied in each subgroup under the two conditions (baseline and
LPS stimulation), a Wilcoxon paired data statistical test was
performed. For each test, P < 0.05 was considered significant.
Results
The baseline characteristics of the neutropenic patients and
non-neutropenic patients are summarized in Table 1.
Table 2 presents the monocyte cytokine production under
basal conditions and after LPS exposure, in cultured mono-
cytes isolated from the blood of neutropenic patients with
ARDS or from non-neutropenic septic ARDS patients and
healthy control individuals.
In monocytes from healthy control individuals, the cytokine lev-
els – both proinflammatory and anti-inflammatory – increased
significantly from baseline levels in response to LPS, demon-
strating the reactivity of normal monocytes. Monocytes from
non-neutropenic septic ARDS patients showed a similar
response, albeit from significantly higher baseline levels than
control individuals (except for IL-1). There was a significant
increase in all cytokines in response to LPS – reaching levels
that were significantly higher than those of control individuals,Available online http://ccforum.com/content/12/1/R17
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Table 1
Medical characteristics of the patients
Patient Hematologic disease Cause of ARDS Cancer status Stem cell transplantation Chemotherapy Neutropenia 
and G-CSF 
treatment
1 Acute myeloid leukemia Bacterial 
pneumonia
Newly 
diagnosed
No Cytosine arabinoside + 
daunorubicin
Yes
2 Hodgkin's disease Bacterial 
pneumonia
Complete 
remission
Peripheral autologous 
blood stem cell 
transplantation
Vincristin + bleomycin + 
doxorubicin
Yes
3 Non-Hodgkin's lymphoma Bacteremia Newly 
diagnosed
No Cyclophosphamide + 
methotrexate + vincristin 
+ doxorubicin
Yes
4 Acute myeloid leukemia Fungal 
pneumonia
Newly 
diagnosed
No Cytosine arabinoside + 
daunorubicin
Yes
5 Non-Hodgkin's lymphoma Bacterial 
pneumonia
Complete 
remission
Allogeneic hematopoietic 
stem cells
Cyclophosphamide + 
vincristin + doxorubicin
Yes
6 Acute myeloid leukemia Bacterial 
pneumonia
Relapse Allogeneic hematopoietic 
stem cells
Cyclophosphamide + 
methotrexate + cytosine 
arabinoside + vincristin 
+ daunorubicin
Yes
7 Non-Hodgkin's lymphoma Septic shock Complete 
remission
Peripheral autologous 
blood stem cell 
transplantation
Cyclophosphamide + 
doxorubicin
Yes
8 Chronic lymphocytic leukemia Septic shock Partial 
remission
Peripheral autologous 
blood stem cell 
transplantation
Cyclophosphamide + 
doxorubicin
Yes
9 Acute lymphoblastic leukemia Fungal 
pneumonia
Newly 
diagnosed
No Cyclophosphamide + 
daunorubicin + vincristin
Yes
10 Non-Hodgkin's lymphoma Bacterial 
pneumonia
Newly 
diagnosed
No Cyclophosphamide + 
methotrexate + vincristin 
+ doxorubicin
Yes
11 Hodgkin's disease Septic shock Complete 
remission
No Vincristin + bleomycin + 
doxorubicin
No
12 Thymoma Bacterial 
pneumonia
Complete 
remission
Peripheral autologous 
blood stem cell 
transplantation
Melphalan No
13 Esophageal cancer Bacterial 
pneumonia
Complete 
resection
No Surgery No
14 Acute myeloid leukemia Fungal 
pneumonia
Newly 
diagnosed
No Cytosine arabinoside + 
daunorubicin
No
15 Rectal cancer Viral pneumonia Complete 
resection
No Surgery No
16 Breast cancer Candidemia Complete 
resection
No Surgery + epirubicin + 
taxotere
No
17 Esophageal cancer Bacterial 
pneumonia
Complete 
resection
No Surgery No
18 Stomach cancer Bacterial 
pneumonia
Complete 
resection
No Surgery No
29 Esophageal cancer Mediatinis Complete 
resection
No Surgery No
20 Esophageal cancer Bacterial 
pneumonia
Complete 
resection
No Surgery No
21 Breast cancer Bacterial 
pneumonia
Complete 
resection
No Surgery + epirubicin + 
taxotere
No
22 Bladder cancer Bacterial 
pneumonia
Complete 
resection
No Surgery No
ARDS = acute respiratory distress syndrome; G-CSF = granulocyte colony-stimulating factor.Critical Care    Vol 12 No 1    Mokart et al.
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demonstrating an increased reactivity of these monocytes.
Monocytes from neutropenic septic ARDS patients, however,
showed baseline levels similar to control individuals, demon-
strating a suppressed state. These levels did not increase in
response to LPS and were therefore significantly lower than
LPS-responsive monocytes from control individuals and non-
neutropenic septic ARDS patients, demonstrating the hypore-
activity of these monocytes.
The analysis of available clinical data showed that the mortality
rate was significantly higher in neutropenic patients than in
non-neutropenic patients, although the PaO2/FiO2 ratio and
the Simplified Acute Physiology Score II were comparable
between the two groups (Table 3).
Discussion
Our results show that cultured monocytes isolated from the
blood of neutropenic septic ARDS patients are suppressed,
as evidenced by low baseline cytokine levels, and are hypore-
active in response to LPS stimulation, as evidenced by an
absence of cytokine increase, compared with monocytes from
non-neutropenic septic ARDS patients and healthy control
individuals.
These results correlate with our previous study suggesting
that neutropenic patients with septic ARDS exhibited a local
pulmonary immunosuppression related to alveolar macro-
phage deactivation [6], but also exhibited a deeply hyporeac-
tive monocytic/macrophagic response. Indeed, we had
previously shown in these patients that bronchoalveolar lavage
had a low cellularity with a predominance of alveolar macro-
phages. HLA-DR was downregulated and the LPS-induced
macrophagic cytokine response was decreased, both of these
features underlining a severe hyporeactive state. This local
macrophage hyporeactivity was associated with a state of
severe alveolar neutropenia contributing to local host immuno-
suppression. The systemic monocytic hyporeactivity found in
the present study can only contribute to this host
immunosuppression.
Since all neutropenic patients exhibited a profound leukopenia
(leukocyte count <100/mm3) we were not able to evaluate
monocyte HLA-DR expression using a flow cytometer (data
not shown). Speculating that our results are in line with previ-
ous evidence of a systemic deactivation of monocyte antigen
or leukocytes described in septic patients [11], however, is
tempting. Monocyte deactivation evidenced by loss of HLA-
DR has been shown to occur early in septic patients and per-
sisting deactivation correlates with mortality [7]. Leukocyte
hyporesponsiveness in cytokine production to LPS has been
shown in sepsis due to both Gram-negative and Gram-positive
pathogens [8]. A more complete phenotypic and functional
characterization of monocyte deactivation, termed immunopa-
ralysis, has been described in which loss of HLA-DR and
cytokine hyporesponsiveness are still the main components
[11].
The mechanisms of such a hyporeactive state are unclear and
are probably multifactorial, related to sepsis [12],
chemotherapy [13] or neutropenia per se. First of all, the evo-
lution of sepsis follows a biphasic immunological pattern: the
early hyperinflammatory phase is counterbalanced by an anti-
Table 2
Cytokine production at baseline and after lipopolysaccharide induction for neutropenic patients and for non-neutropenic patients 
and control individuals
Cytokine Control individuals (n = 10) Non-neutropenic patients (n = 12) Neutropenic patients (n = 10)
Spontaneous production
TNFα 25 (10–50) 100 (10–400)*† 10 (10–10)
IL-1 20 (15–45) 30 (15–870) 15 (15–15)
IL-6 85 (10–115) 5,580 (20–19,560)*† 45 (9–61)
IL-1 receptor antagonist 205 (90–920) 5,740 (430–9,660)*† 175 (74–713)
IL-10 15 (5–45) 50 (5–870)*† 5 (5–5)
Lipopolysaccharide-induced production
TNFα 280 (125–970)*‡ 1,830 (560–3,570)*†‡ 10 (10–10)
IL-1 855 (105–1,550)*‡ 7,900 (410–9,120)*†‡ 15 (15–15)
IL-6 6205 (520–8,825)*‡ 53,720 (13,800–79,450)*†‡ 720 (3–1,113)
IL-1 receptor antagonist 1045 (340–2,250)*‡ 19,110 (5,785–39,110)*†‡ 335 (180–780)
IL-10 305 (70–805)*‡ 1,875 (290–3,280)†‡ 5 (5–5)
Data (pg/ml) are expressed as the median and quartile (25th–75th percentiles). P < 0.05 was considered significant: *P < 0.05 versus 
neutropenic patients, using the Mann–Whitney U test; †P < 0.05 versus control individuals, using the Mann–Whitney U test; and ‡P < 0.05 
baseline versus lipopolysaccharide conditions, using the Wilcoxon test.Available online http://ccforum.com/content/12/1/R17
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inflammatory response that may lead to a hypoinflammatory,
immunosuppressed state [12]. This latter condition is associ-
ated with immunodeficiency and monocyte deactivation. Asso-
ciated with sepsis, chemotherapy can induce a
downregulation of cytokine production through a direct cyto-
toxic effect [13]. Interestingly, the decrease of cytokine pro-
duction can occur regardless of the drugs used, suggesting a
nonspecific mechanism [13].
We cannot, however, consider these effects of a decrease in
cytokines due to monocyte hyporeactivity on the host immune
status in septic ARDS patients without discussing their poten-
tial involvement in ARDS. Indeed, cytokine production by
innate immune response cells is a double-edged sword:
impairment leads to immune suppression and infection-related
injury but an increased or decompartmentalized proinflamma-
tory cytokine response is a major component of ARDS [1], and
several studies have shown that, in ARDS or pneumonia, an
increased inflammatory response could be associated with a
worse outcome [14,15]. Furthermore, anti-inflammatory
cytokines are involved in lung repair modulation following injury
[4].
In the present study, the monocyte deactivation observed in
neutropenic patients compared with non-neutropenic patients
concerned both proinflammatory and anti-inflammatory
cytokines. Given the nonexhaustive panel of measured
cytokines and the impossibility of relating measured cytokine
levels to a net proinflammatory or anti-inflammatory balance, it
is impossible to conclude whether the observed hyporeactivity
leads to a proinflammatory or anti-inflammatory imbalance.
Although our study was not designed to study the relationship
between monocyte deactivation and mortality, we observed an
increased mortality in neutropenic ARDS patients (hyporeac-
tive monocytes) compared with non-neutropenic patients with
ARDS (hyperreactive), unexplained by ARDS severity or
patient severity since there was no difference in the PaO2/
FiO2 ratio or the Simplified Acute Physiology Score II between
these groups.
While local immunosuppression is associated with a good
prognosis in non-neutropenic patients with ARDS [16], a sys-
temic immunosuppression (monocyte deactivation, neutrope-
nia) could be inappropriate in neutropenic patients with septic
ARDS and could participate in increased mortality.
All neutropenic patients in the present study received G-CSF
as a supportive treatment – a molecule that induces anti-
inflammatory cytokine secretion [17] and may increase mono-
cyte deactivation – so the observed low-LPS-stimulated pro-
duction in neutropenic patients could be related to the use of
G-CSF. This balance between proinflammatory and anti-
inflammatory response is extremely variable depending on the
trigger. In the study of Hartung and colleagues, the authors
demonstrate that the major effect of G-CSF was a shift toward
an anti-inflammatory cytokine response; in fact, a reduction in
TNF release was obtained with various stimuli except LPS
[17]. The consequences of G-CSF may also influence the evo-
lution of the acute lung injury. In a rat model of acute lung injury
during neutropenia, Azoulay and colleagues showed an
increase of alveolar cell recruitment and pulmonary edema in
G-CSF-treated animals [18]. The authors concluded in their
study that neutropenia recovery could worsen acute lung
injury, with an exacerbation by G-CSF. Moreover, in a clinical
study, Karlin and colleagues also showed that G-CSF-induced
neutropenia recovery was associated with a risk of respiratory
status deterioration [19]. Furthermore, G-CSF could promote
Table 3
Demographic data
Parameter Neutropenic patients Non-neutropenic patients
n 10 12
Simplified Acute Physiology Score II 45 (36–57) 38 (34–62)
Age (years) 50 (41–64) 48 (38–64)
PaO2/FiO2 (mm/Hg) 160 (150–180) 150 (129–176)
Sex (male/female) 7/3 9/3
Mortality rate (%) 80 42*
Duration of neutropenia before ARDS (days) 3 (1–7)
Duration of neutropenia during ARDS (days) 5 (2–10)
Duration of treatment by G-CSF before ARDS (days) 5 (3–9)
Duration of sepsis before monocyte harvesting (days) 3 (0–5) 3 (1–6)
Duration of sepsis before ARDS diagnosis (days) 2 (0–5) 3 (1–5)
Data are expressed as the median and quartile (25th–75th percentiles), numbers or percentages. ARDS = acute respiratory distress syndrome; 
G-CSF = granulocyte colony-stimulating factor. *P < 0.05 for neutropenic patients versus non-neutropenic patients using Fisher's exact test.Critical Care    Vol 12 No 1    Mokart et al.
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the development of ARDS due to pulmonary infections in neu-
tropenic patients [20]. From these data, the use of G-CSF in
this situation remains to be carefully evaluated. Since all
patients received G-CSF in our study, however, there was no
bias because of its use.
Our study has several limitations. We chose to use a control
population with solid organ malignancies; among these few
had undergone chemotherapy, but on the contrary the neutro-
penic patients all received chemotherapy. It is therefore possi-
ble that chemotherapeutic agents may account for some
differences in cytokine production. In the present study we did
not analyze other parameters reflecting monocyte functions,
such as phagocytic engulfment, peptide recognition or migra-
tion; as a consequence, we cannot rule out other aspects of
monocyte function being preserved. Finally, we did not study
cell surface epitopes that may also be involved in the
decreased production of cytokines in neutropenic patients.
If there is, as we can assume from our results, a parallel
between alveolar and systemic cellular response, a monitoring
of lung defense mechanisms could be proposed through the
study of baseline and LPS-induced cytokine production over
time in monocytes isolated from blood samples. Additionally,
measurement of circulating concentrations of inflammatory
mediators could be useful to evaluate, and possibly target, the
best time for the administration of immunomodulating agents
[21].
The present findings contribute to the debate on the use of
anti-inflammatory treatment in the management of sepsis. A
better understanding of what is the adequate balance of anti-
inflammatory cytokines to proinflammatory cytokines is proba-
bly the key to the improvement of neutropenic septic patients.
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